13189-89-4

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydroxybenzamide is used as an intermediate in the synthesis of a catechol metabolite of dilevalol, which is a pharmaceutical compound with potential applications in the treatment of cardiovascular diseases. The compound plays a crucial role in the production process, contributing to the development of new medications for heart-related conditions.
Used in Chemical Industry:
2,3-Dihydroxybenzamide is also used in the preparation of iron chelating agents. These agents are essential in various applications, such as the treatment of iron overload disorders, water treatment to remove iron contaminants, and in the manufacturing of various industrial products. The compound's ability to form stable complexes with iron ions makes it a valuable component in the development of effective chelating agents.

Upstream product

• 65-45-2 salicylamide 

Downstream Products

• 745078-87-9 2-hydroxy-6-{2-((3-iodophenyl)amino)ethoxy}-N-methylbenzamide 

Relevant academic research and scientific papers

3-Hydroxylation of salicylamide in mice.

Salicylamide is an important model compound for use in investigations concerning drug disposition. In this study the metabolic fate of salicylamide at high doses was evaluated in male mice using HPLC methodology. The concentrations of salicylamide and its metabolites were determined in urine and in blood at various times after the administration of 2 or 4 mmol kg-1 salicylamide. Salicylamide, gentisamide, and their glucuronide and sulfate conjugates were detected. 2,3-Dihydroxybenzamide, the 3-hydroxy metabolite of salicylamide, as well as its glucuronide and sulfate conjugates, were identified and quantitated for the first time by HPLC. 2,3-Dihydroxybenzamide had previously been detected only as a minor metabolite of salicylamide by paper chromatography. However, in the present study, 18% of the salicylamide metabolites appearing in urine after either dosage of salicylamide were 3-hydroxylation products. When a previously published HPLC method for salicylamide analysis was used, 2,3-dihydroxybenzamide glucuronide coeluted with salicylamide glucuronide. The possible formation of 3-hydroxy metabolites must be evaluated in any study of drug metabolism using salicylamide as a model compound.

Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors

Di, tri and tetrahydroxybenzohydroxamic acids, amides and the corresponding di, tri and tetrahydroxy substituted phenylalkanohydroxamic acids, amides and phenyl esters, ribonucleotide reductase inhibitors.

Hydroxybenzohydroxamic acids, benzamides and esters as ribonucleotide reductase inhibitors

Di and trihydroxybenzohydroxamic acids, amides, alkyl substituted amides and phenyl esters, ribonucleotide reductase inhibitors.

HYDROXY BENZOHYDROXAMIC ACIDS AND BENZAMIDES

Di or trihydroxybenzohydroxamic acids or N-substituted benzamides, inhibitors or ribonucleotide reductase